FrancophonIA/ELRC3.0 huggingface dataset:
English: Counsel patients to remain within proximity of a qualified clinical facility for at least 4 weeks following infusion and to seek immediate medical attention should signs or symptoms of CRS occur.
Croatian: Bolesnicima savjetujte da još najmanje 4 tjedna nakon infuzije ostanu u blizini kvalificirane bolničke ustanove i da odmah potraže medicinsku pomoć ako primijete znakove ili simptome CRS-a.
English: HBV reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells.
Croatian: U bolesnika liječenih lijekovima usmjerenim protiv B-stanica može doći do reaktivacije HBV-a, koja u nekim slučajevima rezultira fulminantnim hepatitisom, zatajenjem jetre ili smrću.
English: After you are given YESCARTA
Croatian: Nakon što ste primili lijek YESCARTA
English: Monitoring of vital signs and organ functions should be considered depending on the severity of the reaction.
Croatian: Ovisno o težini nuspojava, potrebno je razmotriti praćenje vitalnih znakova i funkcija organa.
English: The availability of YESCARTA must be confirmed prior to starting the lymphodepleting regimen.
Croatian: Prije započinjanja režima limfocitne deplecije potrebno je potvrditi dostupnost lijeka YESCARTA.
English: Serious adverse reactions including encephalopathy (22%), aphasia (4%), delirium (4%), and seizures (1%) have been reported in patients administered YESCARTA.
Croatian: U bolesnika koji su primali lijek YESCARTA prijavljene su ozbiljne nuspojave, uključujući encefalopatiju (22%), afaziju (4%), delirij (4%) i napadaje (1%).
English: Primary central nervous system (CNS) lymphoma
Croatian: Primarni limfom središnjeg živčanog sustava
English: YESCARTA 0.4 - 2 x 108 cells dispersion for infusion axicabtagene ciloleucel (CAR+ viable T cells) For intravenous use only.
Croatian: NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA YESCARTA 0,4 - 2 x 108 stanica disperzija za infuziju aksikaptagen ciloleucel (CAR+ vijabilne T-stanice) Samo za intravensku primjenu.
English: Consider alternate immunosuppressants if no improvement or if condition worsens.
Croatian: Ako ne dođe do poboljšanja ili ako se stanje pogorša, razmisliti o zamjenskim imunosupresivima.
English: Anti-CD19 CAR T cell levels decreased toward background levels by Month 3 after infusion.
Croatian: Tri mjeseca nakon infuzije, razine anti-CD19 CAR T-stanica snizile su se na osnovne vrijednosti.
English: Preparation of YESCARTA
Croatian: Priprema lijeka YESCARTA
English: Due to the on-target, off-tumour effect of YESCARTA, a period of B-cell aplasia is expected following treatment.
Croatian: Nakon liječenja očekuje se razdoblje aplazije B-stanica zbog ciljanog učinka lijeka YESCARTA na netumorske stanice (engl. on-target, off-tumor effect).
English: A total of 108 patients were treated with YESCARTA in a phase 1/2 open-label, multicentre, singlearm study in patients with relapsed or refractory aggressive B-cell NHL.
Croatian: DLBCL, PMBCL i DLBCL nastao iz folikularnog limfoma (ZUMA-1) Ukupno 108 bolesnika liječeno je lijekom YESCARTA u otvorenom, multicentričnom ispitivanju faze 1/2 s jednom skupinom bolesnika s relapsnim ili refraktornim agresivnim NHL-om B-stanica.
English: Neurologic adverse reaction grading and management guidance
Croatian: Tablica 2: Smjernice za stupnjevanje i liječenje neuroloških nuspojava
English: Neurologic adverse reactions
Croatian: Neurološke nuspojave
English: Unspecified pathogen infections Viral infections
Croatian: Infekcije i infestacije vrlo često infekcije neodređenim patogenima virusne infekcije bakterijske infekcije često gljivične infekcije
English: YESCARTA is stable at room temperature for up to 3 hours after thaw.
Croatian: Nakon odmrzavanja lijek YESCARTA stabilan je na sobnoj temperaturi do 3 sata.
English: It is unknown whether YESCARTA is excreted in human milk or transferred to the breast-feeding child. Breast-feeding women should be advised of the potential risk to the breast-fed child.
Croatian: Nije poznato izlučuje li se YESCARTA u majčino mlijeko ili prenosi u dojenče.
English: Vomiting Constipation Abdominal pain Dry mouth
Croatian: Poremećaji probavnog sustava vrlo često proljev mučnina povraćanje konstipacija bol u abdomenu suha usta često disfagija*
English: HCP Educational program
Croatian: Edukacijski program za zdravstvene radnike
English: Kite Pharma EU B.V. Science Park 406
Croatian: Science Park 406
English: Patients who experience Grade 2 or higher CRS (e.g. hypotension, not responsive to fluids, or hypoxia requiring supplemental oxygenation) should be monitored with continuous cardiac telemetry and pulse oximetry.
Croatian: Oni uključuju primjenu tocilizumaba ili tocilizumaba i kortikosteroida za umjereni, teški ili opasan po život CRS kako je sažeto prikazano u tablici 1. Bolesnike s CRS-om 2. ili višeg stupnja (npr. hipotenzija, izostanak odgovora na tekućine ili hipoksija koja zahtijeva primjenu dodatnog kisika) treba pratiti kontinuiranom srčanom telemetrijom i pulsnom oksimetrijom.
English: How you are given YESCARTA
Croatian: Kako se daje lijek YESCARTA
English: CRS Grade (a)
Croatian: Tablica 1: Smjernice za stupnjevanje i liječenje CRS-a Stupanj CRS-a (a)
English: Assessment of immunoglobulin levels and B-cells in newborns of mothers treated with YESCARTA should be considered.
Croatian: U novorođenčadi čije su majke liječene lijekom YESCARTA treba razmotriti procjenu razina imunoglobulina i B-stanica.
English: Other outcomes were consistent with those of the mITT population.
Croatian: Drugi ishodi bili su u skladu s onima u modificiranoj populaciji planiranoj za liječenje.
English: Motor dysfunction Pain in extremity Back pain Arthralgia Muscle pain
Croatian: Poremećaji mišićno-koštanog sustava i vezivnog tkiva vrlo često poremećaji motorike bol u rukama ili stopalima bol u leđima artralgija bol u mišićima
English: 24-month analysis
Croatian: analiza nakon 12 mjeseci analiza nakon 24 mjeseca analiza nakon 12 mjeseci analiza nakon 24 mjeseca
English: Kite Pharma EU B.V. Science Park 408
Croatian: Science Park 408
English: Adverse drug reactions identified with YESCARTA
Croatian: Tablica 3: Nuspojave zabilježene kod primjene lijeka YESCARTA
English: To prepare YESCARTA, patient's own T cells are harvested and genetically modified ex vivo by retroviral transduction to express a chimeric antigen receptor (CAR) comprising a murine anti-CD19 single chain variable fragment linked to CD28 co-stimulatory domain and CD3-zeta signalling domain.
Croatian: Za pripremu lijeka YESCARTA, bolesniku se uzimaju T-stanice i genetički modificiraju ex vivo retroviralnom transdukcijom za ekspresiju kimeričnog antigenskog receptora (engl.
English: Grade 1
Croatian: Tufsteen 1
English: Dizziness Aphasia
Croatian: Produljene citopenije
English: - have problems with your nervous system (such as fits, stroke, or memory loss).
Croatian: Obratite se svom liječniku prije nego primite lijek YESCARTA ako: - imate problema sa živčanim sustavom (npr. napadaje, moždani udar ili gubitak pamćenja) - imate problema s bubrezima - imate mali broj krvnih stanica (u krvnoj slici)
English: • Inspect the product bag for any breaches of container integrity before thawing.
Croatian: • Vrećicu lijeka pregledajte prije odmrzavanja kako biste provjerili da nema nikakvih oštećenja.
English: • YESCARTA is a one-time treatment.
Croatian: • Lijek YESCARTA primit ćete samo jednom.
English: Dispersion for infusion
Croatian: OBLIK I SADRŽAJ Disperzija za infuziju
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
Croatian: SADRŽAJ PO TEŽINI, VOLUMENU ILI DOZNOJ JEDINICI LIJEKA Jedna sterilna vrećica za infuziju.
English: •Update reports:
Croatian: Napomena:
English: Contents of the pack and other information What YESCARTA contains
Croatian: Kako čuvati lijek YESCARTA Sadržaj pakiranja i druge informacije
English: See section 4.4 for monitoring and management guidance.
Croatian: Smjernice za praćenje i liječenje vidjeti u dijelu 4.4.
English: Cytokine Release Syndrome Hypogammaglobulinaemia
Croatian: Poremećaji imunološkog sustava vrlo često sindrom otpuštanja citokina hipogamaglobulinemija često preosjetljivost hematofagična histiocitoza
English: Evaluation for haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) should be considered in patients with severe or unresponsive CRS.
Croatian: U bolesnika s teškim CRS-om ili CRS-om bez odgovora na liječenje potrebno je razmisliti o provedbi pretrage na hemofagocitnu limfohistiocitozu / sindrom aktivacije makrofaga (engl. haemophagocytic lymphohistiocytosis/macrophage activation syndrome, HLH/MAS).
English: Discuss pregnancy with your doctor if you have received YESCARTA.
Croatian: Ako ste primili lijek YESCARTA, o trudnoći se posavjetujte s liječnikom.
English: Monitor blood counts after YESCARTA infusion.
Croatian: Nakon infuzije lijeka YESCARTA potrebno je nadzirati krvnu sliku.
English: B-cell aplasia leading to hypogammaglobulinaemia can occur in patients receiving treatment with YESCARTA.
Croatian: U bolesnika liječenih lijekom YESCARTA može se pojaviti aplazija B-stanica koja dovodi do hipogamaglobulinemije.
English: YESCARTA is made from your own white blood cells and should only be given to you.
Croatian: Lijek YESCARTA izrađen je isključivo iz Vaših vlastitih stanica.
English: These reactions are presented by system organ class and by frequency.
Croatian: Nuspojave su navedene prema klasifikaciji organskih sustava i učestalosti.
English: There is limited experience with YESCARTA in patients ≥ 75 years of age.
Croatian: ≥ 75 godina su ograničena.
English: Cryostor CS10
Croatian: ECOG 1
English: Respiratory, thoracic and mediastinal disorders Very common
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja vrlo često kašalj dispneja hipoksija pleuralni izljev često plućni edem
English: - Changes in the rhythm or rate of the heartbeat.
Croatian: Poremećaji bubrega i mokraćnog sustava često bubrežna insuficijencija
English: Monitor patients life-long for secondary malignancies.
Croatian: Moguću pojavu sekundarnog maligniteta treba pratiti u bolesnika cijeli život.
English: To inform and explain to patients
Croatian: Uputa o lijeku: Informacije za bolesnika
English: 12-month analysis
Croatian: 6.3 Rok valjanosti
English: • The YESCARTA product bag must not be removed from the cassette if the information on the patient-specific label does not match the intended patient.
Croatian: • Vrećicu lijeka YESCARTA izvadite iz kazete tek nakon potvrđenog identiteta bolesnika.
English: System Organ Class (SOC)
Croatian: Klasifikacija organskih sustava Učestalost
English: Ataxia Neuropathy Seizure
Croatian: Prijavljivanje nuspojava
English: Monitor patients daily for signs and symptoms of CRS for at least 10 days following infusion at the qualified clinical facility.
Croatian: Bolesnika je potrebno svakodnevno nadzirati tijekom najmanje 10 dana nakon infuzije u kvalificiranoj bolničkoj ustanovi zbog moguće pojave znakova i simptoma CRS-a.
English: The following side effects have been reported with YESCARTA.
Croatian: Nuspojave navedene u nastavku zabilježene su uz primjenu lijeka YESCARTA.
English: Further information on Mayzent can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Mayzent.
Croatian: Više informacija o lijeku Mayzent dostupno je na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/Mayzent.
English: The dose is then progressively increased to reach the ‘maintenance' dose on the sixth day.
Croatian: Doza se potom postupno povećava dok se ne dostigne doza „održavanja” šestog dana.
English: The maintenance dose is either 1 mg or 2 mg daily, depending on how quickly the patient's body can process the medicine.
Croatian: Doza održavanja iznosi 1 mg ili 2 mg dnevno, ovisno o tome koliko brzo tijelo bolesnika može preraditi lijek.
English: Treatment is started with a dose of 0.25 mg daily for two days.
Croatian: Liječenje započinje dozom od 0,25 mg dnevno tijekom dva dana.
English: What is Mayzent and what is it used for?
Croatian: Što je Mayzent i za što se koristi?
English: What measures are being taken to ensure the safe and effective use of Mayzent?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Mayzent?
English: The most common side effects with Mayzent (which may affect more than 1 in 10 people) are headache and hypertension (high blood pressure).
Croatian: Najčešće nuspojave lijeka Mayzent (mogu se javiti u više od 1 na 10 osoba) jesu glavobolja i hipertenzija (povišen krvni tlak).
English: Mayzent is available as tablets and should be taken once a day.
Croatian: Lijek Mayzent dostupan je u obliku tableta i uzima se jedanput na dan.
English: Other information about Mayzent
Croatian: Ostale informacije o lijeku Mayzent
English: This is determined by the use of a blood or saliva test to measure the activity of the patient's liver enzyme CYP2C9.
Croatian: To se određuje uzimanjem uzorka krvi ili sline bolesnika kako bi se izmjerila aktivnost jetrenog enzima CYP2C9.
English: The European Medicines Agency therefore decided that Mayzent should only be used in patients whose disease is active with signs of inflammation.
Croatian: Europska agencija za lijekove stoga je odlučila da se Mayzent treba koristiti samo u bolesnika čija je bolest aktivna sa znakovima upale.
English: Mayzent must also not be used in patients who have inherited a gene known as CYP2C9*3 from both parents, which makes them unable to process the medicine fast enough.
Croatian: Mayzent se ne smije koristiti ni u bolesnika koji su naslijedili gen CYP2C9*3 od oba roditelja, zbog čega nisu sposobni dovoljno brzo preraditi lijek.
English: Side effects reported with Mayzent are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Mayzent pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: The medicine must also not be used in patients who previously had certain severe infections (known as progressive multifocal leukoencephalopathy or cryptococcal meningitis).
Croatian: Lijek se ne smije koristiti ni u bolesnika koji su preboljeli određene teške infekcije (kao što su progresivna multifokalna leukoencefalopatija ili kriptokokni meningitis).
English: It is used in patients with active disease, which means that patients still have relapses or signs of inflammation can be seen in scans.
Croatian: Koristi se u bolesnika u kojih je bolest aktivna, što znači da još uvijek dolazi do relapsa (ponovne pojave bolesti) ili da se znakovi upale mogu vidjeti na snimkama.
English: What are the risks associated with Mayzent?
Croatian: Koji su rizici povezani s lijekom Mayzent?
English: Mayzent must also not be used in patients with cancer and certain immune disorders due to its effect on the immune system.
Croatian: Mayzent se ne smije koristiti ni u osoba oboljelih od raka ili osoba s određenim poremećajima imunosnog sustava zbog njegova učinka na imunosni sustav.
English: Mayzent must not be used in patients who are hypersensitive (allergic) to siponimod, or to peanut, soya or any of the other ingredients of the medicine.
Croatian: Mayzent se ne smije davati bolesnicima koji su preosjetljivi (alergični) na siponimod, kikiriki, soju ili bilo koji drugi sastojak lijeka.
English: Why is Mayzent authorised in the EU?
Croatian: Zašto je lijek Mayzent odobren u EU-u?
English: Mayzent is a medicine used to treat adults with an advanced form of MS known as secondary progressive MS (MS).
Croatian: Mayzent je lijek koji se koristi za liječenje odraslih osoba s uznapredovalim oblikom multiple skleroze (MS) poznatim pod nazivom sekundarna progresivna multipla skleroza (SPMS).
English: It must not be used in patients who have recently had a stroke and in patients with certain heart disorders (because of its effects on heart rate and blood pressure), severe liver disorders and in pregnant women and women who can become pregnant and are not using effective contraception.
Croatian: Ne smije se koristiti ni u osoba koje su nedavno imale moždani udar ili imaju određene srčane poremećaje (zbog njegovih učinaka na srčani ritam i krvni tlak), ozbiljne poremećaje jetrene funkcije kao ni u trudnica ili žena reproduktivne dobi koje ne upotrebljavaju pouzdanu kontracepciju.
English: As for all medicines, data on the use of Mayzent are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Mayzent kontinuirano se prate.
English: The company that markets Mayzent will ensure that doctors expected to prescribe the medicine receive educational materials, including a checklist covering the necessary screening, pre-treatment and longterm monitoring of patients.
Croatian: Tvrtka koja stavlja u promet lijek Mayzent osigurat će da liječnici za koje se očekuje da će propisivati lijek dobiju edukacijske materijale, koji obuhvaćaju i kontrolni popis za potreban probir, prethodno liječenje i dugoročno praćenje bolesnika.
English: An overview of Mayzent and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Mayzent i zašto je odobren u EU-u
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mayzent have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Mayzent nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: Disease progression was defined as worsening of the disease that is independent from a relapse and is maintained over at least 3 months, as assessed using a standard scale called EDSS.
Croatian: Ono se definira kao pogoršanje bolesti, neovisno o relapsu, u trajanju od barem tri mjeseca, što se ocjenjuje uz pomoć standardne proširene ljestvice za ocjenu stupnja onesposobljenosti (EDSS).
English: In MS, the immune system (the body's defences) attacks and damages the protective sheath around the nerves in the brain and spinal cord.
Croatian: Kod multiple skleroze imunosni sustav (obrambeni sustav tijela) napada i oštećuje zaštitnu ovojnicu živaca u mozgu i leđnoj moždini.
English: The active substance in Mayzent, siponimod, blocks the action of some receptors (targets) on cells called sphingosine-1-phosphate receptors, which are involved in the movement of lymphocytes (immune cells) around the body.
Croatian: Djelatna tvar lijeka Mayzent, siponimod, onemogućuje djelovanje određenih receptora (meta) na stanicama koji se nazivaju receptori sfingozin 1-fosfata i utječu na kretanje limfocita (imunosnih stanica) kroz tijelo.
English: Mayzent was effective at delaying the progression of secondary progressive MS in patients with active disease; however, the beneficial effects of the medicine were not demonstrated in patients without an active disease.
Croatian: Lijek Mayzent pokazao se učinkovitim u usporavanju napredovanja SPMS-a u bolesnika s aktivnom bolešću; međutim pozitivni učinci lijeka nisu dokazani u bolesnika u kojih bolest nije aktivna.
English: The Agency therefore decided that Mayzent's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Stoga je Agencija zaključila da koristi od lijeka Mayzent nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u EU-u.
English: How does Mayzent work?
Croatian: Kako djeluje Mayzent?
English: The materials will include a guide for patients with key safety information about Mayzent, as well as a pregnancy reminder card for women who can become pregnant.
Croatian: Materijali će obuhvaćati i priručnik za bolesnike s najvažnijim informacijama o sigurnoj primjeni lijeka Mayzent i karticu s podsjetnikom o trudnoći za žene reproduktivne dobi.
English: By attaching to these receptors, siponimod stops lymphocytes from travelling from the lymph nodes towards the brain and spinal cord, thus limiting the damage they cause in MS.
Croatian: Vezivanjem na te receptore siponimod zaustavlja kretanje limfocita od limfnih čvorova prema mozgu i leđnoj moždini, čime ograničava oštećenja koja oni uzrokuju u slučaju multiple skleroze.
English: During the study, 25% of patients with active secondary progressive MS taking Mayzent had disease progression compared with 35% of patients taking placebo (a dummy treatment).
Croatian: Tijekom ispitivanja napredovanje bolesti zabilježeno je u 25 % bolesnika s aktivnim SPMS-om koji su primali lijek Mayzent, u usporedbi s 35 % bolesnika koji su primali placebo (prividno liječenje).
English: For more information about using Mayzent, see the package leaflet or contact your doctor or pharmacist.
Croatian: Za više informacija o primjeni lijeka Mayzent pročitajte uputu o lijeku odnosno obratite se liječniku ili ljekarniku.
English: The side effects with Mayzent are similar to those with another medicine (fingolimod) for MS working in a similar way, and are considered acceptable.
Croatian: Nuspojave lijeka Mayzent slične su onima drugog lijeka (fingolimoda) protiv multiple skleroze koji djeluje na sličan način i smatraju se prihvatljivima.
English: Mayzent can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the management of MS.
Croatian: Mayzent se izdaje samo na recept, a liječenje treba započeti i nadzirati liječnik s iskustvom u liječenju multiple skleroze.
English: What benefits of Mayzent have been shown in studies?
Croatian: Koje su koristi od lijeka Mayzent utvrđene u ispitivanjima?
English: Mayzent was shown to be effective at delaying the progression of the disease in a 3-year main study involving 1,651 patients with secondary progressive MS, of whom 779 had active disease with a relapse within 2 years or other signs of inflammation in scans.
Croatian: Tijekom trogodišnjeg glavnog ispitivanja kojim je bio obuhvaćen 1 651 bolesnik sa SPMS-om, od čega je njih 779 imalo aktivan oblik bolesti s relapsom unutar dvije godine ili drugim znakovima upale na snimkama, utvrđeno je da se lijekom Mayzent uspješno usporava napredovanje bolesti.
English: For the full list of side effects and restrictions of Mayzent, see the package leaflet.
Croatian: Potpuni popis nuspojava i ograničenja povezanih s primjenom lijeka Mayzent potražite u uputi o lijeku.
English: Always check with them if you are not sure.
Croatian: Uvijek provjerite s njima ako niste sigurni.
English: Date of latest renewal: 26 May 2016
Croatian: Datum posljednje obnove: 26. svibanj 2016.
English: In very rare cases breathing might stop.
Croatian: U vrlo rijetkim slučajevima, disanje može prestati.
English: Read all of this leaflet carefully, before you start giving this medicine because it contains important information for you.
Croatian: Pažljivo pročitajte cijelu uputu prije nego počnete davati ovaj lijek jer sadrži Vama važne podatke.
English: Please discuss with your doctor if you need further advice.
Croatian: Molimo porazgovarajte s liječnikom ako Vam je potreban dodatni savjet.
English: This is extremely important, as using more than one medicine at the same time can strengthen or weaken the effect of the medicines involved.
Croatian: To je iznimno važno, jer istodobno uzimanje više od jednog lijeka može pojačati ili oslabiti učinak lijekova o kojima se radi.
English: Always give this medicine exactly as a doctor has told you.
Croatian: Uvijek dajte ovaj lijek točno onako kako Vam je rekao liječnik.
English: The safety and efficacy of midazolam in children aged 0 to 3 months has not been established.
Croatian: Sigurnost i djelotvornost midazolama u djece u dobi od 0 do 3 mjeseca nisu ustanovljene.
English: BUCCOLAM with food and drink
Croatian: BUCCOLAM s hranom i pićem
English: Only move them if they are in danger from, for example, deep water, fire or sharp objects.
Croatian: Pomaknite dijete jedino ako je u opasnosti od, primjerice, duboke vode, vatre ili oštrih predmeta.
English: If the child is having a seizure, allow their body to move freely, do not try to restrain them.
Croatian: Ako dijete ima napadaj, dopustite slobodne pokrete tijela, ne pokušavajte ih ograničavati.
English: Check with a doctor or pharmacist if you are not sure.
Croatian: Provjerite s liječnikom ili ljekarnikom ako niste sigurni.